finerenone

Overview

Finerenone is a non-steroidal mineralocorticoid receptor antagonist used as a therapy in cardiorenal disease. By antagonizing mineralocorticoid receptor signaling, it is associated with anti-inflammatory and anti-fibrotic effects, which are relevant to diseases characterized by progressive kidney injury, albuminuria, fibrosis, and cardiovascular complications. In recent biomedical literature, finerenone has been studied primarily in the context of diabetic kidney disease (DKD) and heart failure, with expanding interest in other chronic kidney disease populations.

Unlike older steroidal mineralocorticoid receptor antagonists, finerenone has been developed as a more selective non-steroidal agent and has attracted attention for its potential to improve both renal and cardiovascular outcomes. Recent studies also suggest broader mechanistic relevance to pathways such as autophagy pathways and tissue fibrosis, including work in peritoneal fibrosis and myocardial remodeling.

Focus of Latest Publications

Recent publications on finerenone have focused heavily on real-world effectiveness and safety in cardiorenal disease, especially diabetic kidney disease (DKD) and chronic kidney disease (CKD) associated with type 2 diabetes. Several observational studies examined finerenone use in routine practice, including cohorts from China and Saudi Arabia, as well as analyses of prescribing patterns in the United States. These reports were motivated by the fact that, although finerenone has shown cardiorenal benefit in randomized trials, real-world evidence remains limited in some populations and settings. One U.S. analysis also highlighted that finerenone appears infrequently used in clinical practice despite its established role in reducing kidney disease progression, cardiovascular events, and heart failure outcomes.

Other recent studies explored whether patient characteristics modify finerenone’s renal effects. In CKD associated with type 2 diabetes, one study evaluated whether pre-treatment estimated glomerular filtration rate trajectory influences finerenone’s renoprotective effect on kidney function and albuminuria. Another study in people with CKD, type 2 diabetes, and a history of nephrectomy reported that finerenone reduced albuminuria versus placebo capsules similarly in patients with and without nephrectomy, with generally comparable treatment-emergent and serious adverse event rates. Additional work in IgA nephropathy assessed finerenone both with ACEI/ARB therapy and in combination with sodium glucose cotransporter-2 (SGLT2) inhibitors, reflecting interest in how finerenone may fit into broader renoprotective regimens.

Finerenone has also been studied beyond kidney disease. In heart failure with mildly reduced or preserved ejection fraction, investigators assessed the transportability of the FINEARTS-HF trial to a real-world U.S. population and performed a Bayesian analysis of efficacy and safety, both reinforcing the relevance of the trial findings for clinical practice. In a swine model of repetitive pressure overload, oral finerenone reduced myocardial interstitial fibrosis but did not improve left ventricular chamber stiffness, suggesting that antifibrotic effects may not directly translate into improved diastolic mechanics in that model. Another preclinical study examined finerenone in peritoneal fibrosis, aiming to determine whether it alleviates fibrosis by restoring autophagy flux in peritoneal mesothelial cells.

A smaller number of publications extended finerenone research into other experimental settings. One rat study examined finerenone, alone or with bosentan, in a model involving benign prostatic hyperplasia and cardiac dysfunction. Another medicinal chemistry paper discussed mineralocorticoid receptor antagonists in the context of finerenone’s approval and ongoing interest in this drug class, but did not evaluate finerenone itself experimentally. Overall, the recent literature emphasizes finerenone’s expanding real-world use, its role in DKD and CKD, and continued investigation of its effects in heart failure and fibrotic disease models.

Key Publications

• NEWJul Finerenone Exposure and Ischemic Stroke in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Propensity Score-Matched Cohort Study. (Clinical medicine (London, England), 2026, PMID 42398671): "Finerenone has demonstrated benefits on composite renal and cardiovascular outcomes in randomized trials; however, ischemic stroke has generally been evaluated as part of composite endpoints, and real-world evidence focusing on this outcome remains limited."
• NEWJul Real-world outcomes of Finerenone in patients with diabetic kidney disease in Saudi Arabia. (PloS one, 2026, PMID 42384643): "Finerenone, a novel nonsteroidal and selective mineralocorticoid receptor antagonist (MRA), has demonstrated substantial cardiorenal benefits in clinical trials; however, real-world data, especially from Saudi Arabia, remain limited."
• NEWJun The interplay of bosentan and finerenone in amelioration of cardiac dysfunction within benign prostatic hyperplasia in rats. (Molecular biology reports, 2026, PMID 42377399): "We tried in current experiment to explore the role of bosentan (BOS) and/or finerenone (FIN) in this lesion."
• NEWJun Finerenone Prescriptions in the United States (2021-2024) by Physician Specialty: Analysis of Use and Potential in the Cardiovascular-Kidney-Metabolic Space. (Journal of the American Heart Association, 2026, PMID 42261987): "Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated greater receptor selectivity and fewer adverse effects compared with older mineralocorticoid receptor antagonists."
• Jun Finerenone Attenuates Peritoneal Fibrosis by Restoring Autophagy Flux. (Nephrology (Carlton, Vic.), 2026, PMID 42209198): "Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has shown potent anti-fibrotic and anti-inflammatory effects in cardiorenal diseases, yet its role in peritoneal fibrosis remains incompletely understood."
• May Real-world effectiveness and safety of finerenone in diabetic kidney disease with preserved eGFR: a retrospective study in China. (BMC nephrology, 2026, PMID 42121102): "this study aimed to evaluate the effectiveness and safety of finerenone in DKD patients."
• May Transportability of the comparative effect of finerenone for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction of ≥40%: insights from the FINEARTS-HF trial. (Journal of comparative effectiveness research, 2026, PMID 42089841): "This study evaluated the transportability of the FINEARTS-HF trial, which assessed finerenone in patients with heart failure (HF) and left ventricular ejection fraction ≥40%, to a real-world US population."
• May Effectiveness and Safety of Finerenone in Patients With Diabetic Kidney Disease: A Real-World Observational Study. (Diabetes, obesity & metabolism, 2026, PMID 42082185): "Finerenone is approved for the treatment of diabetic kidney disease (DKD), but real-world evidence remains limited."
• May Mineralocorticoid Receptor Antagonists With an Acylurea as a Key Polar Interaction Motif. (ChemMedChem, 2026, PMID 42060830): "The recent approval of finerenone for diabetic kidney disease, along with expanding opportunities to treat chronic kidney disease and heart failure with preserved ejection fraction has led to a continued interest in MR antagonism."
• May Pre-treatment estimated glomerular filtration rate trajectory modifies the renoprotective effect of finerenone in patients with chronic kidney disease associated with type 2 diabetes. (Journal of diabetes and its complications, 2026, PMID 41855767): "we aimed to investigate whether pre-treatment estimated glomerular filtration rate (eGFR) trajectory modifies the effects of finerenone on kidney function and albuminuria in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) (CKD-T2D)."